Sort   by:  
 Page size 
ProteomicsHNE-modification identification of ApoAI
In this research, two 4-hydroxy-2-nonenal modified peptides with differential performance were identified in the plasma of patients with coronary artery disease, whether their antibodies were different in the plasma of patients with coronary artery disease and healthy people.
ORGANISM(S): Homo sapiens (Human) 
2024-07-03 | PXD041969 | Pride
Two 4-hydroxy-2-nonenal Apolipoprotein ai Coronary artery disease Autoantibody 
MetabolomicsArginine starvation kills tumor cells through aspartate exhaustion and mitochondrial dysfunction
Defective arginine synthesis, due to the silencing of argininosuccinate synthase 1 (ASS1), is a common metabolic vulnerability in cancer, known as arginine auxotrophy. Understanding how arginine depletion kills arginine-auxotrophic cancer cells will facilitate the development of anti-cancer therapeu...
2019-11-07 | MTBLS745 | MetaboLights
TranscriptomicsDNMT3L promotes quiescence in postnatal spermatogonial progenitor cells
We analyzed transcriptome profiles of postnatal germ cells and demonstrated that DNMT3L is important for spermatogonial stem/progenitor cell development Examination of wild-type and Dnmt3l knockout smaples in postnatal male germ cells
ORGANISM(S): Mus musculus 
2014-07-03 | E-GEOD-54411 | biostudies-arrayexpress
UnknownRamucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Not available
S-EPMC6946880 | biostudies-literature
UnknownRobust estimation of bacterial cell count from optical density.
Not available
S-EPMC7499192 | biostudies-literature
UnknownEffects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Not available
S-EPMC12274867 | biostudies-literature
UnknownEffects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Not available
S-EPMC7615591 | biostudies-literature
UnknownImpact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Not available
S-EPMC7618536 | biostudies-literature
UnknownFrailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Not available
S-EPMC11390031 | biostudies-literature
UnknownEmpagliflozin in Patients with Chronic Kidney Disease.
Not available
S-EPMC7614055 | biostudies-literature
Sort   by:  
 Page size